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DISCUSSION 161
Neutralizing antibodies against the E protein are generally considered as a primary correlate of 162 protection against flaviviruses (5, 15). However, some preclinical studies suggested that several NS 163 proteins when used as immunogen for vaccination alone or in combination could induce some degree 
173
The live-attenuated JE-CVax vaccine is a chimeric flavivirus that consist of the genome of YFV-17D 174 from which the prM/E genes have been replaced by those of JEV SA14-14-2. We, therefore, used JE-
175
CVax to assess whether it can offer, besides protection against JEV, also protection against YFV 176 challenge. Since AG129 mice are highly susceptible to lethal JEV SA14-14-2 and YFV-17D infection 177 ( Fig. S8, (28, 33) ), we used these two vaccine strains as established surrogates for wt-JEV (33) and wt-178 YFV (34, 35), respectively (demanding lower biosafety containment for handling). A single dose of JE-
179
CVax provided in addition to the expected protection against JEV challenge, a near to complete 180 protection (35/36) against a massive 1000x-LD50 challenge with YFV ( Fig. 1B) . The protective activity 181 against YFV was raised fast, and a survival benefit could be observed already within 7 days after 182 vaccination (Fig. 1C) . These observations were further corroborated by the fact that vaccination of 183 immunocompetent C57BL/6 mice with a single dose of JE-CVax provided complete protection (21/21) 184 against lethal intracranial challenge (17, 23) with YFV ( Fig. 1D and Fig 4E) . This activity of JE-CVax 185 was YFV-specific, as AG129 mice that had been vaccinated with Ixiaro ® (the inactivated JEV vaccine) 186 were not protected against lethal YFV challenge. Furthermore, mice that had been vaccinated with JE-
187
CVax and that later survived YFV challenge did not survive a subsequent lethal challenge with the ZIKV 188 ( Fig. S1 ).
189
Others have shown in mice that cross-reactive antibodies (together with cross-reactive T cells) may 
216
Although, we show that JE-CVax immunization resulted in complete protection against YFV-induced 217 disease, there were variations in the actual levels of anti-YFV nAbs post YFV challenge. In some 218 animals, no nAbs were detected against YFV post YFV-17D-challenge. This lack of YFV nAb provides 219 strong evidence that JE-CVax even conferred sterilizing immunity in these mice. Since, such protection 220 cannot be explained by nAb against the YFV-prM/E, it may be accredited to non-nAbs (42-44) and/or 221 adaptive cellular immunity (16, 30, 32, 45) . Some correlation between anti-NS1 antibody levels and the 
281
To conclude, we demonstrate that JE-CVax efficiently and rapidly induces high cross-protective efficacy 282 (~100%) in mice against YFV challenge, even with an exceedingly aggressive challenge inoculum. The 
MATERIALS and METHODS 289
Cells and medium. BHK-21J and Vero E6 cells used in this study were a generous gift from Peter 
337
An MHC I class-restricted peptide from YFV-17D non-structural protein 3 (NS3) (sequence ATLTYRML)
338
(57) was synthetized by Eurogentec (Seraing, Belgium). Total cellular antigen for YFV-17D and JEV 339 SA14-14-2 was prepared first by infecting Vero E6 cells with 0.1 MOI YFV-17D or JEV SA14-14-2, 
377
Hyper-immune serum was prepared by vaccinating AG129 mice with 10 4 PFU JE-CVax, followed by 378 two boosts with 10 5 PFU JE-CVax in 14-day intervals. Another 14 days after the second booster, animals 379 were bled twice per week for the following four weeks. All serum batches were then pooled and CPENT 380 assays for JE-CVax and YFV-17D were performed. We did not observe any YFV nAbs in the 381 hyperimmune-sera but did see a ~3.6-fold (log10CPENT50 titers 3.03  0.18) selective increase in 382 neutralizing titers against JE-CVax compared to single vaccination. (Fig. 3A) . Normal mouse control 383 serum was prepared by pooling serum from 18 non-vaccinated AG129 mice.
384
Immunocompetent wt-C57BL/6JOIaHsd i.e. C57BL/6 were purchased from ENVIGO Labs, Netherlands 385 and were maintained and manipulated as described for AG129 mice with some modifications (23, 28).
386
Since, flaviviruses do not readily replicate in immunocompetent wild type mice (28), they were 
Plaque assay and plaque reduction neutralization test (PRNT). Viral titers of YFV-17D or JE-CVax

405
preparations were determined using plaque assays on BHK-21J cells. In brief, 10 6 BHK-21J cells per 406 well were plated in 6-well plates and cultured overnight in seeding medium. Cells were washed with 407 PBS and inoculated with virus of different dilutions prepared in the assay medium for one hour at room 408 temperature (RT). Culture supernatants of uninfected cells were used as negative controls. Cells were 409 thoroughly washed with the assay medium and overlaid with MEM-2X (Gibco, Belgium) supplemented 410 with 4% FCS and 0.75% sodium bicarbonate containing 0.5% low melting agarose (Invitrogen, USA).
411
The overlay was allowed to solidify at RT, cells were then cultured for 7 days at 37 C, fixed with 8% 412 formaldehyde and stained with methylene blue. Plaques were manually counted and plaque titer was 413 determined as PFU/ml.
414
Throughout the study, all the virus neutralization assays i.e. PRNT and CPE-based virus neutralization 430 cells/well were plated in 96-well plates overnight in seeding medium. The medium was then replaced 431 with assay medium containing different virus dilutions and cultured for 5 days at 37C. Later, assays 432 were first visually scored for CPE and then stained with MTS/Phenazine methosulphate (PMS; Sigma-498 nm for each well. All assays were performed in six replicates and TCID50/ml was determined using 435 the Reed and Muench method (70).
436
CPENT assays were performed in a similar way as the CPE assays for viral titration with some analysis. (A, B) Exclusion of debris was achieved by gating out the FSC-low population in a FSC-A vs SSC-A plot. Then, only single cells were retained by elimination of the high SSC-W population, in a SSC-W vs SSC-H plot. In a subsequent step, live cells were selected by gating out the Zombie Aqua-positive population as shown here in an NS1-eGFP/FSC-A vs ZA plot. Finally for the detection of anti-NS1 antibodies (A) cells were gated based on positivity for NS1-eGFP and positivity/negativity of -NS1 Ab PE-Cy7. (B) For intracellular cytokine staining, based on positivity for CD3e (eFluor450-conjugated) and negativity (CD4) or positivity for CD8a (APC/Cy7-conjugated), CD4 + and CD8 + T cell populations were defined as CD3 + CD8and CD3 + CD8 + populations, respectively. Finally, cells were gated based on positivity/negativity for IFN- and positivity/negativity of TNF-. Samples from non-vaccinated mice were used to set the boundaries that define cells positive and negative for intracellular markers. 
